Anzeige
Mehr »
Dienstag, 02.06.2026 - Börsentäglich über 12.000 News
Entsteht hier die nächste Quantum-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
221 Leser
Artikel bewerten:
(1)

Future Market Insights: Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to USD 12.79 billion by 2036, expanding at a CAGR of 7.8% during the forecast period. According to Future Market Insights (FMI), the market is being reshaped by increasing demand for personalized medications, expanding adoption of specialty therapies, rising prevalence of chronic diseases, and growing preference for customized dosage formulations across diverse patient populations.

As healthcare providers increasingly seek patient-specific therapeutic solutions, compounding pharmacies are playing a critical role in delivering customized medications that address unique dosing requirements, allergy concerns, flavor modifications, and unavailable commercial formulations. Growing utilization across pain management, hormone replacement therapy, dermatology, pediatrics, and veterinary medicine is further strengthening market expansion.

Sabyasachi?Ghosh, Principal Consultant, FMI notes:?

"The demand for compounding pharmacies in USA is transitioning from volume-driven growth toward value-led differentiation. Organizations that align product development with regulatory compliance, patient-specific requirements, and evolving therapeutic applications will be best positioned to strengthen market leadership through 2036. Supply chain reliability, quality assurance, and customized treatment capabilities remain central to buyer decision-making across healthcare settings."

Get detailed market forecasts, competitive benchmarking, and pricing trends:https://www.futuremarketinsights.com/reports/sample/rep-us-978

Market Drivers and Strategic Shifts

The market is witnessing sustained momentum due to increasing clinical adoption of personalized therapies, broader utilization of compounded medications across specialty care settings, and growing patient demand for customized treatment options.

Healthcare providers are increasingly turning to compounding pharmacies to address medication shortages, create patient-specific dosage strengths, improve treatment adherence, and support populations requiring specialized formulations unavailable through conventional pharmaceutical channels.

Key growth drivers include:

  • Rising demand for personalized medicine and patient-centric healthcare solutions
  • Growing prevalence of chronic pain, hormone disorders, dermatological conditions, and pediatric treatment needs
  • Increasing adoption of customized dosage forms and allergy-free formulations
  • Expansion of specialty pharmacy services and home healthcare delivery models
  • Growing veterinary medicine applications requiring customized medications
  • Improved reimbursement coverage and broader healthcare access
  • Expansion of 503A pharmacy operations supporting patient-specific prescriptions

However, the market continues to face challenges including regulatory compliance complexity, quality assurance requirements, supply chain constraints, rising operational costs, and increasing scrutiny surrounding compounding standards and patient safety.

Segment and Regional Insights

The 503A Pharmacies segment is expected to dominate the pharmacy type category with a 65.0% share in 2026, supported by strong patient-specific prescription demand, established procurement channels, and widespread physician adoption.

By product type, Oral Medication is projected to account for 33.0% of market demand in 2026, reflecting continued preference for customized oral dosage forms across multiple therapeutic applications.

Among therapeutic areas, demand remains particularly strong across:

  • Pain Management
  • Hormone Replacement Therapy (HRT)
  • Dermatology
  • Pediatrics
  • Veterinary Medicine

Regionally

  • South is projected to be the fastest-growing regional market with an 8.1% CAGR, supported by healthcare infrastructure expansion and increasing treatment access.
  • Midwest is expected to grow at 7.9% CAGR, driven by aging rural populations, centralized hospital procurement, and veterinary healthcare demand.
  • West continues to benefit from strong adoption of integrative medicine, dermatology treatments, and anti-aging therapies.
  • Northeast maintains growth through academic medical centers, specialty pharmacy concentration, and pediatric healthcare demand.

Customize insights for your business?strategy: https://www.futuremarketinsights.com/customization-available/rep-us-978

Competitive Landscape

The market remains highly competitive, with established compounding pharmacy providers, specialty pharmacy operators, and personalized medicine specialists competing through service quality, regulatory compliance, product customization capabilities, and geographic reach.

Key companies include:

  • Fagron N.V.
  • Avella Specialty Pharmacy
  • Central Admixture Pharmacy Services Inc.
  • Hoye's Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Cantrell Drug Company
  • Clinigen Group
  • Dougherty's Pharmacy

Competitive strategies are increasingly focused on:

  • Expansion of sterile compounding capabilities
  • Investment in 503B outsourcing facilities
  • Growth of personalized medicine service offerings
  • Geographic expansion across underserved markets
  • Strengthening regulatory compliance and quality assurance programs
  • Development of specialty therapeutic formulations
  • Enhancement of home delivery and patient support services

Recent industry developments include Fagron N.V.'s 2025 expansion of sterile compounding and personalized medicine capabilities through investments in 503B outsourcing facilities, alongside continued expansion of specialty pharmacy and home delivery services across the United States.

Why FMI's Demand for Compounding Pharmacies in USA Report Is Different

Traditional market research typically provides:

  • Market size, CAGR, and forecast
  • Basic segmentation and regional analysis
  • Company profiles and high-level competition analysis

FMI goes significantly deeper with industry-specific intelligence:

  • Therapeutic area demand mapping and adoption trends
  • Regulatory compliance and quality assurance benchmarking
  • Personalized medicine and specialty therapy analysis
  • Pharmacy infrastructure and distribution capability assessment
  • Reimbursement and procurement trend analysis
  • Regional healthcare investment and access mapping
  • Competitive movement tracking including expansions, partnerships, and facility investments

Explore the Latest Healthcare Industry Analysis Now:https://www.futuremarketinsights.com/industry-analysis/healthcare??

Why this matters for buyers?

  • Supports access to patient-specific medication solutions
  • Enhances treatment adherence through customized dosage forms
  • Addresses unmet therapeutic needs where commercial alternatives are unavailable
  • Improves medication accessibility for pediatric, geriatric, and veterinary populations
  • Enables healthcare providers to deliver personalized treatment plans

Who should use this report?

  • Compounding pharmacies
  • Specialty pharmacy providers
  • Healthcare systems and hospitals
  • Pharmaceutical manufacturers
  • Healthcare investors and private equity firms
  • Regulatory and compliance professionals
  • Home healthcare providers
  • Veterinary healthcare organizations

Where it supports action:

  • Sell: Identify high-demand therapeutic categories and customized medication opportunities
  • Source: Evaluate compounding capabilities and supplier quality standards
  • Deploy: Optimize pharmacy operations and patient service delivery
  • Expand: Target high-growth regional markets and therapeutic applications
  • Partner: Identify specialty pharmacy and healthcare collaboration opportunities
  • Invest: Track emerging personalized medicine and compounding pharmacy trends
  • Compete: Benchmark service capabilities, compliance infrastructure, and geographic coverage

Unlock high-growth opportunities with FMI's?niche business market insights:?https://www.futuremarketinsights.com/industry-analysis??

Demand for Compounding Pharmacies in USA Market Size & Industry Trends 2036

  • Market name: Demand for Compounding Pharmacies in USA
  • Market size: USD 6.04 Billion (2026)
  • Forecast value: USD 12.79 Billion (2036)
  • CAGR: 7.8%
  • Forecast period: 2026 to 2036
  • Leading pharmacy type: 503A Pharmacies (65.0% share)
  • Leading product type: Oral Medication (33.0% share)
  • Fastest-growing region: South (8.1% CAGR)
  • Second fastest-growing region: Midwest (7.9% CAGR)
  • Key therapeutic areas: Pain Management, HRT, Dermatology, Pediatrics, Veterinary Medicine
  • Key companies: Fagron N.V., Avella Specialty Pharmacy, Central Admixture Pharmacy Services Inc., Hoye's Pharmacy, Vertisis Custom Pharmacy, Smith Caldwell Drug Store, Sixth Avenue Medical Pharmacy, Cantrell Drug Company, Clinigen Group, Dougherty's Pharmacy

Related Reports:

Advanced Therapeutics Pharmaceutical Outsourcing Market - https://www.futuremarketinsights.com/reports/advanced-therapeutics-pharmaceutical-outsourcing-market

Pharma Peeler Centrifuge Market - https://www.futuremarketinsights.com/reports/pharma-peeler-centrifuge-market

Pharmaceutical Sterility Testing Market - https://www.futuremarketinsights.com/reports/pharmaceutical-sterility-testing-market

Topical Antibiotic Pharmaceuticals Market - https://www.futuremarketinsights.com/reports/topical-antibiotic-rharmaceuticals-market

Biopharmaceutical Contract Manufacturing Market - https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market

About Future Market Insights (FMI)??

Future Market Insights (FMI) delivers actionable, decision-focused market intelligence that goes beyond traditional research reports. The company provides:??

  • In-depth pricing and cost benchmarking analysis??
  • Demand forecasting based on real industry inputs??
  • Procurement and buyer behavior insights??
  • Supply chain and trade flow intelligence??
  • Technology adoption trends across industries??

FMI follows a robust bottom-up research?methodology, combining insights from industry experts, procurement leaders, and technical professionals to ensure?accurate?and practical market intelligence.??

For Press & Corporate Inquiries????

Rahul Singh?????
AVP - Marketing and Growth Strategy?????
Future Market Insights, Inc.?????
+91 8600020075?????
For Sales -?sales@futuremarketinsights.com?????
For Media -?Rahul.singh@futuremarketinsights.com?????
For web -?https://www.futuremarketinsights.com/?????
For?Web -?https://www.factmr.com/?????

Logo - https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/demand-for-compounding-pharmacies-in-usa-to-reach-usd-12-79-billion-by-2036-amid-growing-need-for-personalized-therapies-and-specialized-medication-solutions-302789091.html

© 2026 PR Newswire
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.